Skip to main content

Advertisement

SpringerLink
Log in

Serum C-reactive protein as an important prognostic variable in patients with diffuse large B cell lymphoma

  • Research Article
  • Published:
Tumor Biology

Abstract

C-reactive protein (CRP) is an acute-phase reactant that is a promising biomarker in patients with cancer of many kinds. The aim of this retrospective study was to evaluate significant changes in CRP levels as a parameter for the response effect and long-term survival of patients with diffuse large B cell lymphoma (DLBCL). Serum CRP data were collected in 94 patients with DLBCL from October 2006 to August 2009 in Cancer Center, Sun Yat-Sen University. Results were correlated with clinical data. The median CRP serum level in patients with DLBCL was 30.91 ± 53.35 in male and 22.39 ± 29.89 mg/L in female. Base line CRP levels were correlated with International Prognostic Index (IPI) scores (p = 0.03). Among the patients with an IPI score of 1–2, base line CRP levels were correlated with long-term survival (p = 0.001). Base line CRP levels were also correlated with OS (p = 0.001) and varied with different clinical stages (p = 0.03). The corresponding CRP levels in the patients with 2 cycles of chemotherapy were correlated with short-term treatment response (p = 0.003) and OS (p = 0.04) or TTP (p = 0.03). CRP serum levels can be used as additional prognostic parameter in patients with diffuse large B cell type lymphoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Marnell L, Mold C, Du Clos TW. C-reactive protein: ligands, receptors and role in inflammation. Clin Immunol. 2005;117:104–11.

    Article  CAS  Google Scholar 

  2. Hoffmann JA, Kafatos FC, Janeway CA, Ezekowitz RA. Phylogenetic perspectives in innate immunity. Science. 1999;284:1313–8.

    Article  CAS  Google Scholar 

  3. Deodhar SD. C-reactive protein: the best laboratory indicator available for monitoring disease activity. Cleve Clin J Med. 1989;56:126–30.

    Article  CAS  Google Scholar 

  4. Paffen E, DeMaat MP. C-reactive protein in atherosclerosis: a causal factor? Cardiovasc Res. 2006;71:30–9.

    Article  CAS  Google Scholar 

  5. Eberhard OK, Langefeld I, Kuse ER, et al. Procalcitoninin in the early phase after renal transplantation—will it add to diagnostic accuracy? Clin Transplant. 1998;12:206–11.

    CAS  PubMed  Google Scholar 

  6. Crumley AB, McMillan DC, McKernan M, Going JJ, Shearer CJ, Stuart RC. An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastroesophageal cancer. Br J Cancer. 2006;94:1568–71.

    Article  CAS  Google Scholar 

  7. Hashimoto K, Ikeda Y, Korenaga D, et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer. 2005;103:1856–64.

    Article  CAS  Google Scholar 

  8. Kodama J, Miyagi Y, Seki N, et al. Serum C-reactive protein as a prognostic factor in patients with epithelial ovarian cancer (1999). Eur J Obstet Gynecol Reprod Biol. 1999;82:107–10.

    Article  CAS  Google Scholar 

  9. Nakanishi H, Araki N, Kudawara I, et al. Clinical implications of serum C-reactive protein levels in malignant fibrous histiocytoma. Int J Cancer. 2002;99:167–70.

    Article  CAS  Google Scholar 

  10. Lossos IS, Morgensztern D. Prognostic factors in diffuse large B cell lymphoma: present and future. Am Soc Clin Oncol. 2007;1092-9118/07/496-501.

    Google Scholar 

  11. Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. JAMA. 2004;291:585–90.

    Article  CAS  Google Scholar 

  12. Shimada H, Nabeya Y, Okazumi S, et al. Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol. 2003;83:248–52.

    Article  Google Scholar 

  13. Heikkila K, Ebrahim S, Lawlor DA. A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Commun Health. 2007;61:824–32.

    Article  Google Scholar 

  14. Hefler LA, Concin N, Hofstetter G, et al. Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res. 2008;14(3):710–4.

    Article  CAS  Google Scholar 

  15. Stephan Polterauer S, Christoph Grimm C, Clemens Tempfer C, et al. C-reactive protein is a prognostic parameter in patients with cervical cancer. Gynecol Oncol. 2007;107:114–7.

    Article  Google Scholar 

  16. Khandavilli SD, Ceallaigh P, Lloyd CJ, et al. Serum C-reactive protein as a prognostic indicator in patients with oral squamous cell carcinoma. Oral Oncol. 2009;45:912–4.

    Article  CAS  Google Scholar 

  17. Legouffea E, Rodriguez C, Picgtc MC. C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin’s lymphoma. Leuk Lymphoma. 1998;31(3–4):351–7.

    Article  Google Scholar 

  18. Khalifa KA, Alkilani AA, Ismail H. Evaluation of some biochemical markers as prognostic factors in malignant lymphoma. J Egypt Nat Cancer Inst. 2006;20(1):47–54.

    Google Scholar 

  19. Sergei IG, Florian RG, Michael K. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–99.

    Article  Google Scholar 

  20. Herishanu Y, Perry C, Braunstein R. Early-mid treatment C-reactive protein level is a prognostic factor in aggressive non-Hodgkin’s lymphoma. E J Haematol. 2007;79(2):150–4.

    Article  CAS  Google Scholar 

  21. Koukourakis MI, Kambouromiti G, Pitsiava D, Tsousou P, Tsiarkatsi M, Kartalis G. Serum C-reactive protein (CRP) levels in cancer patients are linked with tumor burden and are reduced by anti-hypertensive medication. Inflammation. 2009;32(3):169–75.

    Article  CAS  Google Scholar 

  22. Gage JR, Fonarow G, Hamilton M, Widawski M, Martínez-Maza O, Vredevoe DL. Beta blocker and angiotensin-converting enzyme inhibitor therapy is associated with decreased Th1/Th2 cytokine ratios and inflammatory cytokine production in patients with chronic heart failure. Neuroimmunomodulation. 2004;11:173–80.

    Article  CAS  Google Scholar 

  23. Lee CC, Adler AI, Sandhu MS, Sharp SJ, Forouhi NG, Erqou S, Luben R, Bingham S, Khaw KT, Wareham NJ. Association of C-reactive protein with type 2 diabetes: prospective analysis and meta-analysis. Diabetologia. 2009;52(6):1040–7.

    Article  CAS  Google Scholar 

  24. Gortney JS, Sanders RM. Impact of C-reactive protein on treatment of patients with cardiovascular disease. Am J Health Syst Pharm. 2007;64:2009–16.

    Article  CAS  Google Scholar 

  25. Schmeisser A, Soehnlein O, Illmer T, Lorenz HM, Eskafi S, Roerick O, Gabler C, Strasser R, Daniel WG, Garlichs CD. ACE inhibition lowers angiotensin II-induced chemokine expression by reduction of NF-kappaB activity and AT1 receptor expression. Biochem Biophys Res Commun. 2004;325:532–40.

    Article  CAS  Google Scholar 

Download references

Acknowledgment

We thank for the generous help in the linguistic review from Chuan Shen, Ph.D. in Dana-Farber Cancer institute and Harvard Medical School and Dongrong Situ, M.D. in Sun Yat-sen University Cancer Center. This work was supported by the National Natural Science Foundation of China Grant 30500610, Talents Training Program of Sun Yat-sen University, and National “Eleventh Five” technology major projects—Clinical evaluation of new drug technology platform 2008ZXO9312-002.

Author information

Authors and Affiliations

  1. State Key Laboratory of Oncology, South China, Guangzhou, Guangdong, 510060, People’s Republic of China

    Ye Cao, Yan-xia Shi, Yu-ting Tan, Yu-Chen Cai, Hui-yan Luo, Miao-zhen Qiu, Xiu-yu Cai, Ying Jin, Yue-li Sun & Wen-qi Jiang

  2. Department of Medical Oncology, Cancer Center, Sun Yat-sen University, 651 Dongfeng East Road, Guangzhou, Guangdong Province, 510060, People’s Republic of China

    Ye Cao, Yan-xia Shi, Yu-ting Tan, Yu-Chen Cai, Hui-yan Luo, Miao-zhen Qiu, Xiu-yu Cai, Ying Jin, Yue-li Sun & Wen-qi Jiang

  3. Department of Statistics and Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou, Guangdong, 510080, People’s Republic of China

    Jing-ou Chen

Authors
  1. Ye Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yan-xia Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jing-ou Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yu-ting Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yu-Chen Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hui-yan Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Miao-zhen Qiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Xiu-yu Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ying Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yue-li Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Wen-qi Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wen-qi Jiang.

Additional information

Ye Cao and Yan-xia Shi contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cao, Y., Shi, Yx., Chen, Jo. et al. Serum C-reactive protein as an important prognostic variable in patients with diffuse large B cell lymphoma. Tumor Biol. 33, 1039–1044 (2012). https://doi.org/10.1007/s13277-012-0337-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-012-0337-z

Keywords

Search

Navigation